Selective product in-licensing or acquisition will enable Context Therapeutics to rapidly build a diversified pipeline of drugs to treat hormone response cancers.
SOURCE. Academia, startup, or pharma.
STAGE. Preclinical development through Phase 2-ready.
TYPE. Small molecule or biologic.
DRUG AND REAGENT TOOLKITS. The best ideas are often developed through external collaboration. To facilitate collaboration, our Team makes available to academic labs and private research institutes our "Toolkits" that contain proprietary compounds, screening assays, reagents, and tools. The goal of these relationships is to expand our current knowledge of Context's Core Indications and to find new uses of our compounds to treat diseases of significant unmet medical need.
Context has ongoing Collaborations with leading research institutions to further our understanding of Sigma1 mechanism of action, drug development, and biomarker identification. The cornerstone of these Collaborations is an unwavering belief that successful Collaborations are driven by an open exchange of scientific ideas, frequent dialogue, and a patient-first philosophy.
Developing the next generation of antihormonal therapies to treat breast, prostate, and ovarian cancers.
Apristor is an investigational New Chemical Entity (NCE) for PR+ breast and ovarian cancers.